CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award Director acquired 4,216 shares (grant or award)
- 4 Grant or award Director acquired 4,216 shares (grant or award)
- 4 Grant or award Director acquired 4,216 shares (grant or award)
- 4 Grant or award Director acquired 4,216 shares (grant or award)
- 4 Grant or award Director acquired 4,216 shares (grant or award)
- 4 Grant or award Director acquired 4,216 shares (grant or award)
- 4 Open-market sale COFO and Secretary sold 10,000 shares at an average $28.60 ($286,044)
- 4 Open-market sale President and CEO sold 25,000 shares at an average $25.15 ($628,720)
- 4 Open-market sale COFO and Secretary sold 10,000 shares at $25.04 ($250,400)
- 4 Open-market sale Chief Medical Officer sold 1,476 shares at $29.40 ($43,394)
- 4 Open-market sale Director sold 2,119 shares at $30.10 ($63,782)
- 4 Open-market sale COFO and Secretary sold 3,497 shares at $30.09 ($105,225)
- 4 Open-market sale President and CEO sold 33,815 shares at an average $30.08 ($1,017,243)
- 4 Open-market sale Chief Medical Officer sold 3,366 shares at an average $30.03 ($101,071)
- 4 Open-market sale President and CEO sold 28,433 shares at an average $29.28 ($832,515)
- 4 Open-market sale Chief Medical Officer sold 1,521 shares at $30.88 ($46,968)
- 4 Open-market sale COFO and Secretary sold 1,521 shares at $30.89 ($46,984)
- 4 Open-market sale Director sold 1,377 shares at $30.88 ($42,522)
- 4 Open-market sale COFO and Secretary sold 10,000 shares at an average $29.53 ($295,339)
- 4 Open-market sale Chief Medical Officer sold 1,459 shares at $28.48 ($41,552)
Page 7 of 22 · 436 filings